Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Blood

• Publication date

  2009-11-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2009-05-220327PMID 19770361PMCID PMC2925478
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

  2009cited by this paper
• Inhibitors of factor VIII in black patients with hemophilia.

  2009cited by this paper
• Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13

  2008cited by this paper
• Helper‐dependent adenoviral gene therapy mediates long‐term correction of the clotting defect in the canine hemophilia A model

  2006cited by this paper
• Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.

  2006cited by this paper
• Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype.

  2004cited by this paper
• Removal of B-domain Sequences from Factor V Rather than Specific Proteolysis Underlies the Mechanism by Which Cofactor Function Is Realized*

  2004cited by this paper
• Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.

  2004cited by this paper
• Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.

  2003cited by this paper
• High Level Expression of Recombinant Porcine Coagulation Factor VIII*

  2002cited by this paper
• Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII.

  2002cited by this paper
• The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion

  2002cited by this paper
• Expression and Characterization of Recombinant Murine Factor VIII

  2002cited by this paper
• Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.

  2001cited by this paper
• Posttranslational modifications of recombinant myotube-synthesized human factor IX.

  2001cited by this paper
• The Canine Factor VIII cDNA and 5’ Flanking Sequence

  1998cited by this paper
• Complete short-term correction of canine hemophilia A by in vivo gene therapy.

  1996cited by this paper
• Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A

  1993cited by this paper
• Coagulant properties of hybrid human/porcine factor VIII molecules.

  1992cited by this paper
• Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus.

  1991cited by this paper
• Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.

  1989cited by this paper
• Subunit structure of thrombin-activated porcine factor VIII.

  1989cited by this paper
• Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.

  1985cited by this paper
• CANINE HEMOPHILIA

  1949cited by this paper

• Enhancing hemophilia A gene therapy by strategic F8 deletions in AAV vectors

  2025cites this paper
• Ancient origin of the furin sequence in the wolf F8 gene

  2025cites this paper
• Factor IXa and Factor X Influence Factor VIIIa Stability and Inactivation Mechanisms In Vitro and In Vivo.

  2025cites this paper
• AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life

  2024cites this paper
• Lack of FVIII detection in humans and dogs with an intron-22 inversion challenges hypothesis regarding inhibitor risk.

  2024cites this paper
• Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy

  2024cites this paper
• Cellular stress and coagulation factor production: when more isn't necessarily better.

  2023cites this paper
• Therapeutic potential of fetal liver cell transplantation in hemophilia A mice

  2023cites this paper
• Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice.

  2023cites this paper
• Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells

  2023cites this paper
• Coagulation Factor VIII Regulates von Willebrand Factor Homeostasis In Vivo.

  2023cites this paper
• Long-Term Follow-up of Liver-Directed, Adeno-Associated Vector-Mediated Gene Therapy in the Canine Model of Hemophilia A.

  2022cites this paper
• Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain

  2022cites this paper
• Molecular therapeutics of hemophilia A and B

  2022cites this paper
• Molecular coevolution of coagulation factor VIII and von Willebrand factor.

  2021cites this paper
• Activated Protein C has a Regulatory Role in Factor VIII Function.

  2021cites this paper
• Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A

  2021cites this paper
• FVIII activity following FVIII protein infusion or FVIII gene transfer predicts the bleeding risk in hemophilia A rats

  2020cites this paper
• A long-term study of AAV gene therapy in hemophilia A dogs identifies clonal expansions of transduced liver cells

  2020cites this paper
• Inhibitors—Recent insights

  2020cites this paper
• Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles

  2020cites this paper
• Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII

  2020cites this paper
• Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.

  2019cites this paper
• Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy

  2018cites this paper
• Evaluation of the activity levels of rat FVIII and human FVIII delivered by adeno-associated viral vectors both in vitro and in vivo.

  2018cites this paper
• Gene Therapy Approaches To Immune Tolerance Induction In Canine Hemophilia

  2018cites this paper
• Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test – Demonstrated in vitro and ex vivo

  2017cites this paper
• Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A

  2016cites this paper
• Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism Soy PhosphatidylinositoleContaining Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domaineDeleted Recombinant Canine Factor VIII in Hemophilia A Dogs

  2016cites this paper
• Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs.

  2016cites this paper
• Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.

  2016cites this paper
• Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies

  2016cites this paper
• In vivo efficacy of platelet-delivered, high specific activity factor VIII variants Short Title: Improving platelet-delivered factor VIII efficacy

  2016cites this paper
• Successful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs

  2016cites this paper
• Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction

  2016cites this paper
• Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment

  2016cites this paper
• Platelet‐delivered therapeutics

  2015cites this paper
• Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors

  2015cites this paper
• Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII

  2015cites this paper
• Gene therapy for hemophilia.

  2015cites this paper
• Adeno-Associated Viral Vector-Driven Expression of Coagulation Proteins for Treatment of Hemophilias and Cancer

  2015cites this paper
• Apoptotic effects of platelet factor VIII on megakaryopoiesis: implications for a modified human FVIII for platelet‐based gene therapy

  2014cites this paper
• Clinical outcome after diagnosis of hemophilia A in dogs.

  2014cites this paper
• Lessons Learned from Animal Models of Inherited Bleeding Disorders.

  2014cites this paper
• Animal models of hemophilia and related bleeding disorders.

  2013cites this paper
• Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.

  2013cites this paper
• Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A

  2013cites this paper
• Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon

  2013cites this paper
• Development and Characterization of Recombinant Ovine Coagulation Factor VIII

  2012cites this paper
• Animal models of hemophilia.

  2012cites this paper
• Porcine Model of Hemophilia A

  2012cites this paper
• AAV-based Neonatal Gene Therapy for Hemophilia A: Long-Term Correction and Avoidance of Immune Responses in Mice

  2012cites this paper
• Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia.

  2012cites this paper
• Light Chain of Factor VIII Is Sufficient for Accelerating Cleavage of von Willebrand Factor by ADAMTS13 Metalloprotease*

  2012cites this paper
• Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.

  2011cites this paper
• CHITOSAN-MEDIATED ORAL GENE THERAPY FOR HEMOPHILIA TREATMENT AND PROPHYLACTIC TOLERANCE

  2011cites this paper
• Using Factor VII in Hemophilia Gene Therapy

  2011cites this paper
• Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog

  2011cites this paper
• Efficacy of engineered FVIII-producing skeletal muscle enhanced by growth factor-releasing co-axial electrospun fibers.

  2011cites this paper
• Ectopic platelet-delivered factor (F) VIII for the treatment of Hemophilia A: Plasma and platelet FVIII, is it all the same?

  2011cites this paper
• Engineering Factor Viii for Hemophilia Gene Therapy.

  2011cites this paper
• In vivo efficacy of platelet-delivered, high specific activity factor VIII variants.

  2010cites this paper
• Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.

  2010cites this paper
• Understanding and Improving Platelet-Delivered Factor (F) VIII Hemostatic Efficacy in Hemophilia A Mice

  2010influential citation
• Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B

  2010cites this paper
• Clinical outcome after diagnosis of hemophilia A in dogs

  year unknowncites this paper